Open AccessRisk of Immune Reconstitution Inflammatory Syndrome With Integrase Inhibitors Versus Other Classes of Antiretrovirals: A Systematic Review and Meta-analysis of Randomized Trials
Author(s) -
Ying Zhao,
Ameer Hohlfeld,
Phiona E Namale,
Graeme Meintjes,
Gary Maartens,
Mark E Engel
Publication year - 2022
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002937
Subject(s) - immune reconstitution inflammatory syndrome , medicine , meta analysis , relative risk , randomized controlled trial , confidence interval , raltegravir , efavirenz , integrase inhibitor , antiretroviral therapy , viral load , immunology , human immunodeficiency virus (hiv)
Integrase strand transfer inhibitors (InSTIs) decrease HIV plasma viral load faster than other antiretroviral classes. More rapid viral load decline has been associated with higher risk of immune reconstitution inflammatory syndrome (IRIS). There are conflicting reports on the association between InSTI and IRIS. We performed a systematic review and meta-analysis to compare the risk of IRIS among treatment-naive HIV-positive patients starting InSTI versus non-InSTI regimens.